• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿昔替尼治疗肾细胞癌肺转移近完全缓解后诱发复发性气胸:一种意外的并发症

Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.

作者信息

Socola Francisco, Loaiza-Bonilla Arturo, Benedetto Pasquale

机构信息

Division of Hematology and Oncology, Department of Medicine, Jackson Memorial Hospital and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Suite 3300, 1475 Northwest 12th Avenue, Miami, FL 33136, USA.

出版信息

Case Rep Oncol Med. 2012;2012:390702. doi: 10.1155/2012/390702. Epub 2012 Dec 26.

DOI:10.1155/2012/390702
PMID:23326741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3541576/
Abstract

We report a case of a Caucasian male with a history of renal cell carcinoma metastatic (mRCC) to the lungs refractory despite aggressive treatment with several lines of targeted therapy. He was started on axitinib palliative targeted therapy with a good clinical and radiological response; however one month after treatment initiation he presented to the emergency department with severe dyspnea and hypoxemia. Physical exam and chest X-ray revealed left-sided tension pneumothorax which required emergent thoracostomy with subsequent improvement; however it recurred requiring video assisted thoracoscopy. A left-sided 4 × 3 cm cavitated necrotic lesion was found at the level of the main pulmonary artery. Repair with pericardial fat flap was performed. Surgical biopsies from this lesion revealed mRCC with extensive necrosis. Imaging studies before and after axitinib use showed an initial 4 × 3 cm mass seen in the same location of this large cavitated necrotic tumor. Pneumothorax has not been described as a potential major complication from the use of axitinib. Complete or near-complete responses of mRCC to axitinib targeted therapy may lead to this potential life-threatening complication, particularly if the metastatic lesions are located near to pleural structures. We also review pertinent clinical trial data on axitinib.

摘要

我们报告了一例患有肾细胞癌肺转移(mRCC)的白种男性病例,尽管接受了多线靶向治疗的积极治疗,但病情仍难以控制。他开始接受阿昔替尼姑息性靶向治疗,临床和影像学反应良好;然而,治疗开始一个月后,他因严重呼吸困难和低氧血症被送往急诊科。体格检查和胸部X线检查显示左侧张力性气胸,需要紧急胸腔造口术,随后病情有所改善;然而气胸复发,需要电视辅助胸腔镜检查。在主肺动脉水平发现一个4×3厘米的左侧空洞性坏死病变。采用心包脂肪瓣进行修复。对该病变进行手术活检显示为伴有广泛坏死的mRCC。使用阿昔替尼前后的影像学研究显示,在这个大的空洞性坏死肿瘤的相同位置最初可见一个4×3厘米的肿块。气胸尚未被描述为使用阿昔替尼的潜在主要并发症。mRCC对阿昔替尼靶向治疗的完全或接近完全反应可能会导致这种潜在的危及生命的并发症,特别是如果转移灶位于靠近胸膜结构的位置。我们还回顾了关于阿昔替尼的相关临床试验数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/83f81d481815/CRIM.ONCMED2012-390702.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/ac0255d748c0/CRIM.ONCMED2012-390702.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/965e33f5a988/CRIM.ONCMED2012-390702.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/ba8c14017a65/CRIM.ONCMED2012-390702.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/83f81d481815/CRIM.ONCMED2012-390702.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/ac0255d748c0/CRIM.ONCMED2012-390702.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/965e33f5a988/CRIM.ONCMED2012-390702.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/ba8c14017a65/CRIM.ONCMED2012-390702.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ad/3541576/83f81d481815/CRIM.ONCMED2012-390702.004.jpg

相似文献

1
Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.阿昔替尼治疗肾细胞癌肺转移近完全缓解后诱发复发性气胸:一种意外的并发症
Case Rep Oncol Med. 2012;2012:390702. doi: 10.1155/2012/390702. Epub 2012 Dec 26.
2
Electrocardiographic manifestations in a large right-sided pneumothorax.大量右侧气胸的心电图表现。
BMC Pulm Med. 2021 Mar 23;21(1):101. doi: 10.1186/s12890-021-01470-1.
3
[A Case of Pleural Empyema with Fistula Caused by Endobronchial Metastasis of Renal Cell Carcinoma].[一例因肾细胞癌支气管内转移导致瘘管形成的胸膜脓胸病例]
Hinyokika Kiyo. 2022 Apr;68(4):113-116. doi: 10.14989/ActaUrolJap_68_4_113.
4
Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases.既往使用阿昔替尼治疗进展后的转移性肾细胞癌患者再次使用阿昔替尼治疗取得良好疗效:两例报告
Int Cancer Conf J. 2017 Nov 14;7(1):30-34. doi: 10.1007/s13691-017-0313-y. eCollection 2018 Jan.
5
Unusual case of primary spontaneous hemopneumothorax in a young man with atypical tension pneumothorax: a case report.一名年轻男性原发性自发性血气胸合并非典型张力性气胸的罕见病例:病例报告
J Med Case Rep. 2018 Jul 2;12(1):188. doi: 10.1186/s13256-018-1732-x.
6
Axitinib for the management of metastatic renal cell carcinoma.阿昔替尼治疗转移性肾细胞癌。
Drugs R D. 2011;11(2):113-26. doi: 10.2165/11591240-000000000-00000.
7
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.阿昔替尼作为转移性肾细胞癌二线治疗对124例患者的疗效、安全性及生活质量评估:日本真实世界临床实践经验
Clin Genitourin Cancer. 2017 Feb;15(1):122-128. doi: 10.1016/j.clgc.2016.06.019. Epub 2016 Jul 5.
8
Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.多中心、单臂、Ⅱ期临床研究:二线阿昔替尼治疗转移性肾细胞癌低危患者(FavorAx)
Target Oncol. 2019 Feb;14(1):33-38. doi: 10.1007/s11523-018-0613-y.
9
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.在一家大型综合癌症中心,阿昔替尼治疗转移性肾细胞癌的真实世界前瞻性经验。
Eur J Cancer. 2017 Jul;79:185-192. doi: 10.1016/j.ejca.2017.04.015. Epub 2017 May 13.
10
Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.阿昔替尼治疗纳武利尤单抗治疗失败的转移性肾细胞癌的疗效。
In Vivo. 2020 May-Jun;34(3):1541-1546. doi: 10.21873/invivo.11943.

引用本文的文献

1
Osimertinib-induced severe bilateral pneumothorax: A case report.奥希替尼致严重双侧气胸:病例报告。
Medicine (Baltimore). 2024 Jan 19;103(3):e36994. doi: 10.1097/MD.0000000000036994.
2
Sunitinib: An Unusual Cause of Pneumothorax in a Patient With Metastatic Chromophobe Renal Cell Carcinoma.舒尼替尼:转移性嫌色细胞肾细胞癌患者气胸的罕见病因。
Cureus. 2020 Aug 6;12(8):e9586. doi: 10.7759/cureus.9586.
3
Pericardial fat pad plombage for pulmonary cavity causing massive air leakage.心包脂肪垫充填术治疗导致大量漏气的肺空洞。

本文引用的文献

1
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?对于初始接受 VEGFr-TKI 治疗后进展的转移性肾细胞癌患者,最佳的治疗方法是什么?
Cancer Treat Rev. 2013 Jun;39(4):366-74. doi: 10.1016/j.ctrv.2012.06.010. Epub 2012 Jul 23.
2
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.阿昔替尼对比索拉非尼用于晚期肾细胞癌的疗效(AXIS):一项随机 3 期试验。
Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4.
3
VHL and HIF signalling in renal cell carcinogenesis.
Surg Case Rep. 2020 Jul 1;6(1):156. doi: 10.1186/s40792-020-00917-7.
VHL 和 HIF 信号通路在肾细胞癌发生中的作用。
J Pathol. 2010 Jun;221(2):125-38. doi: 10.1002/path.2689.
4
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.阿昔替尼——一种血管内皮生长因子(VEGF)受体的选择性抑制剂。
Target Oncol. 2009 Dec;4(4):297-305. doi: 10.1007/s11523-009-0126-9. Epub 2009 Oct 30.
5
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.阿昔替尼用于索拉非尼难治性转移性肾细胞癌的II期研究。
J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034. Epub 2009 Aug 3.
6
NCCN clinical practice guidelines in oncology: kidney cancer.美国国立综合癌症网络(NCCN)肿瘤学临床实践指南:肾癌
J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. doi: 10.6004/jnccn.2009.0043.
7
Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.肾细胞癌:ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:81-2. doi: 10.1093/annonc/mdp137.
8
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.细胞因子时代日本转移性肾细胞癌患者的预后:1463 例患者的协作组报告。
Eur Urol. 2010 Feb;57(2):317-25. doi: 10.1016/j.eururo.2008.12.026. Epub 2009 Jan 3.
9
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.阿昔替尼(AG-013736)的非临床抗血管生成和抗肿瘤活性,阿昔替尼是一种口服、强效且选择性的血管内皮生长因子受体酪氨酸激酶1、2、3抑制剂。
Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.
10
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.转移性肾细胞癌(mRCC)的流行病学和社会经济负担:文献综述
Cancer Treat Rev. 2008 May;34(3):193-205. doi: 10.1016/j.ctrv.2007.12.001. Epub 2008 Mar 4.